Eli Lilly’s existing October 2024 evaluation agreement with Peptron remains strictly limited to non-exclusive internal R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, with no commercial rights granted and termination possible on 30 days’ notice. The deal was extended through October 7, 2026, to allow further in-vivo validation and expansion into CNS indications, yet no technology transfer, binding commercial license, or equivalent agreement has been announced despite ongoing joint research. Lilly has instead pursued competing sustained-release platforms such as Camurus’ FluidCrystal and multiple unrelated licensing deals, underscoring that the evaluation phase has not progressed to commercialization within the narrow remaining window.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於13% 機率
$11,464 交易量
$11,464 交易量
2026-10-07
13% 機率
$11,464 交易量
$11,464 交易量
2026-10-07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 evaluation agreement with Peptron remains strictly limited to non-exclusive internal R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, with no commercial rights granted and termination possible on 30 days’ notice. The deal was extended through October 7, 2026, to allow further in-vivo validation and expansion into CNS indications, yet no technology transfer, binding commercial license, or equivalent agreement has been announced despite ongoing joint research. Lilly has instead pursued competing sustained-release platforms such as Camurus’ FluidCrystal and multiple unrelated licensing deals, underscoring that the evaluation phase has not progressed to commercialization within the narrow remaining window.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市場開放時間： May 5, 2026, 8:02 PM ET
交易量
$11,464結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETThis market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 evaluation agreement with Peptron remains strictly limited to non-exclusive internal R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, with no commercial rights granted and termination possible on 30 days’ notice. The deal was extended through October 7, 2026, to allow further in-vivo validation and expansion into CNS indications, yet no technology transfer, binding commercial license, or equivalent agreement has been announced despite ongoing joint research. Lilly has instead pursued competing sustained-release platforms such as Camurus’ FluidCrystal and multiple unrelated licensing deals, underscoring that the evaluation phase has not progressed to commercialization within the narrow remaining window.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,464結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETEli Lilly’s existing October 2024 evaluation agreement with Peptron remains strictly limited to non-exclusive internal R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, with no commercial rights granted and termination possible on 30 days’ notice. The deal was extended through October 7, 2026, to allow further in-vivo validation and expansion into CNS indications, yet no technology transfer, binding commercial license, or equivalent agreement has been announced despite ongoing joint research. Lilly has instead pursued competing sustained-release platforms such as Camurus’ FluidCrystal and multiple unrelated licensing deals, underscoring that the evaluation phase has not progressed to commercialization within the narrow remaining window.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions